Durable Remissions in CLL With Fixed-Duration ... - CLL Support
Durable Remissions in CLL With Fixed-Duration Triplet (Gazyva, Imbruvica, Venclexta) at 4 Years
You need to be a member of this community to see this post.
11 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
Dated 1st September 2019
In a phase III trial of patients with previously untreated CLL...
Good News! BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
3rd April 2020 Blood
Key points to note:
BTK inhibitor therapy achieves durable disease...
End of suspense! Here is Dr. Koffman's ASCO 2020 "Top Pick" #1!
CLL Society's ASCO 2020 Conference Coverage. End of suspense! Here is Dr. Koffman's ASCO Top Pick...
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
Abstract report in New England Journal of Medicine Published February 5, 2025
No real new...
The combinations are here...
The future is getting very bright for CLL patients.
Johnson & Johnson today announced the...
Related Posts
del17p CLL? Overall Survival and Progression-Free Survival Are Improved With Ibrutinib- Frontline Venetoclax/Obinutuzumab Approved in Europe for CLL
- Dr. Shadman on Fixed Durations of Treatment in CLL
continuing the journey - Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL
